Instructions for Heptral (Ademetionine) lyophilisate for solution preparation + solvent
English product name
Heptral®
Release Form
lyophilizate d/400 mg injection r-ra d/w/w/m: fl. 5 pcs. in a complex with a solvent (amp. 5 ml 5 pcs.)
Description Heptral
Lyophilizate for preparation of solution for injection in/in and in/out from practically white to white with a yellowish colour shade; solvent - transparent solution from colorless to light yellow; reduced solution - transparent solution from colorless to yellow.
1 fl
1,4-butandisulfonate ademethionine 760 mg,
which corresponds to the content of the adenomethionine ion 400 mg
Solvent: L-lysine - 342.4 mg, sodium hydroxide - 11.5 mg, water d/i - up to 5 ml.
Type I (5) colorless glass bottles with solvent (amp. 5 ml 5 pcs) - packs of cardboard.
Type I (5) colorless glass bottles with solvent (amp. 5 ml 5 pcs.) - packages of cell contour (1) - packs of cardboard.
ATC codes
A16AA02 Ademetionine
Clinical-pharmacological groups / Group affiliation
Hepatoprotector
Active substance
ademethionine
Pharmaco-therapeutic group
Other preparations for gastrointestinal and metabolism, amino acids and their derivatives
Pharmacological effect Heptral
Hepatoprotector, has anti-depressive activity. It has a choleretic and cholekinetic effect. It has detoxifying, regenerating, antioxidant, antifibrotic and neuroprotective properties.
It makes up for the deficiency of ademethionine and stimulates its production in the body, primarily in the liver and brain. It is involved in biological transmethylation reactions (donator of the methyl group), the molecule S-adenosyl-L-methionine (ademethionine), is a donator of the methyl group in the methylation reactions of phospholipids of cell membranes, proteins, hormones, neurotransmitters; participates in transsulfate reactions as a precursor to cysteine, taurine, glutathione (provides an oxidation-reduction mechanism of cell detoxification), coenzyme acetylation. Increases glutamine content in the liver, cysteine and taurine in the plasma; reduces the amount of methionine in the serum, normalizing metabolic reactions in the liver. In addition to decarboxylation, it is also involved in aminopropylene processes as a precursor to polyamines - putrescine (a stimulant for cell regeneration and hepatocyte proliferation), spermidine and spermine, which are part of the ribosome structure.
Testimony Heptral
- Intrahepatic cholestasis in precirrotic and cirrotic conditions,
- including:
- fatty liver dystrophy;
- chronic hepatitis;
- toxic liver lesions of various etiologies,
- including alcoholic, viral, medicinal (antibiotics, anti-tumour,
- anti-tuberculosis and antiviral drugs,
- tricyclic antidepressants,
- oral contraceptives);
- chronic asphyxiated cholecystitis; cholangitis; cirrhosis; encephalopathy, including those associated with liver failure (including
- alcoholic).
- The duration of treatment is determined individually depending on the severity and course of the disease.
- Liver cholestasis in pregnant women.
- Symptoms of depression.
Method of use, course and dosage Heptral
It is used inwards, muscularly inwards or venomously (very slowly).In a venous or intramuscular injection, the daily dose is 400-800 mg.
The duration of treatment is determined individually depending on the severity and course of the disease.
- Nosology Heptral (ICD codes)
- B15
- Acute hepatitis A
- B16
- Acute hepatitis B
- B17.1
- Acute hepatitis C
- B18.1
- Chronic viral hepatitis B without delta agent
- B18.2
- Chronic viral hepatitis C
- F32
- Depressive episode
- F33
- Recurrent depressive disorder
- K70
- Alcoholic liver disease
- K71
- Toxic liver failure
- K72
- Liver failure not classified in other rubrics (including hepatic coma, hepatic encephalopathy)
- K73
- Chronic hepatitis not classified elsewhere
- K74
- Fibrosis and cirrhosis
- K76.0
- Fatty liver (liver degeneration) not classified elsewhere
- K81.1
- Chronic cholecystitis
- K83.0
- Holangit
- O26.6
- Liver damage during pregnancy, childbirth and the postpartum period
